{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:27Z","timestamp":1790693847009,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.vhri.2026.102122","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:01:49Z","timestamp":1790690509000},"page":"102122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Minimization Analysis of Intravenous and Subcutaneous Daratumumab in Patients With Multiple Myeloma: A Societal and Healthcare System Perspective"],"prefix":"10.1016","volume":"58","author":[{"given":"Giacomo","family":"Berti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fantelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Temporin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Riccoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vhri.2026.102122_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(03)01077-5","article-title":"Management of multiple myeloma: a systematic review and critical appraisal of published studies","volume":"4","author":"Kumar","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vhri.2026.102122_bib2","series-title":"Darzalex, European Medicines Agency (EMA)","year":"2018"},{"issue":"10","key":"10.1016\/j.vhri.2026.102122_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.vhri.2026.102122_bib4","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.vhri.2026.102122_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.vhri.2026.102122_bib6","author":"Giunta"},{"issue":"6","key":"10.1016\/j.vhri.2026.102122_bib9","first-page":"243","article-title":"Indicazioni metodologiche per la valorizzazione economica della perdita di produttivit\u00e0 e dell\u2019informal care nella stima dei costi di malattia. www.epiprev.it","volume":"33","author":"Gianino","year":"2009","journal-title":"Epidemiol Prev"},{"issue":"11","key":"10.1016\/j.vhri.2026.102122_bib12","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.clinthera.2022.09.006","article-title":"Use of resource modeling to quantify the organizational impact of subcutaneous formulations for the treatment of oncologic patients: the case of daratumumab in multiple myeloma","volume":"44","author":"Federici","year":"2022","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.vhri.2026.102122_bib13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/ph18040482","article-title":"Ensuring sustainability in pharmaceutical care: a retrospective analysis of administrative databases on the utilization, costs, and switching patterns of biological therapies in the agency for health protection of the metropolitan area of Milan","volume":"18","author":"Langfelder","year":"2025","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:01:52Z","timestamp":1790690512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926005376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":9,"alternative-id":["S2212109926005376"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102122","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Minimization Analysis of Intravenous and Subcutaneous Daratumumab in Patients With Multiple Myeloma: A Societal and Healthcare System Perspective","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"102122"}}